Gene · 1874
Papers2,563
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,563
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Transcriptomic Analysis of HPV-Positive Oesophageal Tissue Reveals Upregulation of Genes Linked to Cell Cycle and DNA Replication. | Int J Mol Sci | 2024 | 39795915 | PubTator, text mining | PubMed |
| Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. | Signal Transduct Target Ther | 2024 | 39627201 | PubTator, text mining | PubMed |
| FastAd: A versatile toolkit for rapid generation of single adenoviruses or diverse adenoviral vector libraries. | Mol Ther Methods Clin Dev | 2024 | 39559559 | PubTator, text mining | PubMed |
| Study of the Role of E2F1 and TMEM132A in Prostate Cancer Development. | Front Biosci (Landmark Ed) | 2024 | 39473405 | PubTator, text mining | PubMed |
| The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells. | Commun Biol | 2024 | 39341888 | PubTator, text mining | PubMed |
| NUCB2 promotes hepatocellular carcinoma cell growth and metastasis by activating the E2F4/PTGR1 axis. | Int J Biol Sci | 2024 | 39309426 | PubTator, text mining | PubMed |
| Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9. | Int J Oncol | 2024 | 39239750 | PubTator, text mining | PubMed |
| CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer. | Breast Cancer Res Treat | 2024 | 39017815 | PubTator, text mining | PubMed |
| DREAM On, DREAM Off: A Review of the Estrogen Paradox in Luminal A Breast Cancers. | Biomedicines | 2024 | 38927507 | PubTator, text mining | PubMed |
| The p21CIP1-CDK4-DREAM axis is a master regulator of genotoxic stress-induced cellular senescence. | Nucleic Acids Res | 2024 | 38783095 | PubTator, text mining | PubMed |
| E2F-mediated POLA2 upregulation is correlated with macrophage infiltration and poor prognosis in hepatocellular carcinoma. | Transl Cancer Res | 2024 | 38737703 | PubTator, text mining | PubMed |
| Diagnostic and prognostic role of long non-coding RNAs (lncRNAs) in metastatic melanoma patients with BRAF gene mutation receiving BRAF and MEK inhibitors. | Heliyon | 2024 | 38601651 | PubTator, text mining | PubMed |
| POLQ inhibition attenuates the stemness and ferroptosis resistance in gastric cancer cells via downregulation of dihydroorotate dehydrogenase. | Cell Death Dis | 2024 | 38575587 | PubTator, text mining | PubMed |
| Related cellular signaling and consequent pathophysiological outcomes of ubiquitin specific protease 24. | Life Sci | 2024 | 38395384 | PubTator, text mining | PubMed |
| Selective Occupation by E2F and RB of Loci Expressed by RNA Polymerase III. | Cancers (Basel) | 2024 | 38339234 | PubTator, text mining | PubMed |
| Targeting FBXO22 enhances radiosensitivity in non-small cell lung cancer by inhibiting the FOXM1/Rad51 axis. | Cell Death Dis | 2024 | 38296976 | PubTator, text mining | PubMed |
| Y-Box Binding Protein 1: Unraveling the Multifaceted Role in Cancer Development and Therapeutic Potential. | Int J Mol Sci | 2024 | 38255791 | PubTator, text mining | PubMed |
| RBL2 represses the transcriptional activity of Multicilin to inhibit multiciliogenesis. | Cell Death Dis | 2024 | 38253523 | PubTator, text mining | PubMed |
| E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma. | Medicine (Baltimore) | 2024 | 38241554 | PubTator, text mining | PubMed |
| E2F3/5/8 serve as potential prognostic biomarkers and new therapeutic direction for human bladder cancer. | Medicine (Baltimore) | 2024 | 38215110 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1874/papers?page=4